Metastatic pancreatic ductal adenocarcinoma (mPDAC)
Conditions
Interventions
None listed
Sponsors
Servier Affaires Medicales
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adult Patients must meet all the following inclusion criteria to be eligible for the study: 1. 18 years and older (19 years and older for South Korea) 2. Cytologically confirmed mPDAC at initiation of nal-IRI treatment 3. All patients receiving a nal-IRI + 5-flurouracil/leucovorin regimen should have been pre-treated with a gemcitabine-based regimen 4. Initiation of a systemic therapy with nal-IRI (index date) during the study eligibility period (between January 1, 2018, and December 31, 2021) 5. At least one cycle of nal-IRI-containing regimen should have been administered 6. A minimum 1-year survival from the index date (initiation date of nal-IRI-containing regimen) 7. Availability of data related to survival outcomes in the patient medical record 8. Patients deceased or not at the time of enrollment will be eligible for inclusion in the study
Exclusion criteria
Exclusion criteria: Patients meeting any of the following criteria will not be included in the study: 1. No documentation of systemic therapy outcomes or prior treatments in patient medical records 2. Patients with second concomitant metastatic malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not Applicable as data collection is performed to describe population, disease and treatment characteristics. | — |
Secondary
| Measure | Time frame |
|---|---|
| Not Applicable as data collection is performed to describe population, disease and treatment characteristics. | — |
Countries
Japan,Asia(except Japan),Europe
Contacts
Public ContactSatoko Otani
Linical Co., Ltd. Contract Medical Affairs Business unit
Outcome results
None listed